SearchSearch HOME COMPANY PATIENT CENTER PIPELINE INVESTORS NEWS CONTACT US . Introduction message from Nawal Ouzren, CEO of Sensorion. Click link below... Read more Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients Read more Sensorion will be present at the AAO-HNSF 2017, let’s meet Read more Details 29 May 2017 Biopharmaceutical company developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss. Latest news 12 September 2017 Sensorion’s Oral SENS-401 Prevented Cisplatin-Induced Hearing Loss By More than 50 Percent in Preclinical Study Read 25 August 2017 Sensorion in the press “Les Echos” : « une avancée dans les traitements de l’oreille interne » (in French only) Read Company Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more Pipeline Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more Investors Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more Back to Top Sensorion | The inner ear diseases company © 2017 by MLCOM / Webmail / Cloud / Privacy Policy